The first targeted therapy for breast cancer could soon face direct competition.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Waltz, E. GlaxoSmithKline cancer drug threatens Herceptin market. Nat Biotechnol 23, 1453–1454 (2005). https://doi.org/10.1038/nbt1205-1453
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1205-1453
This article is cited by
-
Monoclonals expand into neural disorders
Nature Biotechnology (2006)